Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RLYB
stocks logo

RLYB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
133.33K
+250.87%
-0.147
-41.33%
0.00
-100%
-0.150
-28.57%
0.00
-100%
-0.160
-27.27%
Estimates Revision
The market is revising Upward the revenue expectations for Rallybio Corporation (RLYB) for FY2025, with the revenue forecasts being adjusted by 39.75% over the past three months. During the same period, the stock price has changed by 9.53%.
Revenue Estimates for FY2025
Revise Upward
up Image
+39.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-54.9%
In Past 3 Month
Stock Price
Go Up
up Image
+9.53%
In Past 3 Month
Wall Street analysts forecast RLYB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLYB is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast RLYB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLYB is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.667
sliders
Low
1.00
Averages
1.00
High
1.00
Current: 0.667
sliders
Low
1.00
Averages
1.00
High
1.00
Jones Trading
Catherine Novack
Strong Buy
to
Hold
Downgrades
n/a
2025-04-15
Reason
Jones Trading
Catherine Novack
Price Target
n/a
2025-04-15
Downgrades
Strong Buy
to
Hold
Reason
JonesResearch analyst Catherine Novack downgraded Rallybio to Hold from Buy without a price target after the company announced discontinuation of lead asset RLYB212 in fetal and neonatal alloimmune thrombocytopenia prevention. Rallybio still has promising assets in the pipeline, but Jones needs to see Phase 1 data from early-stage assets before again recommending the shares, the analyst tells investors in a research note.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
to
Hold
Downgrades
n/a
2025-04-09
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
n/a
2025-04-09
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$5
2025-03-17
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$5
2025-03-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$5
2025-02-12
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$5
2025-02-12
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$5
2025-01-13
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$5
2025-01-13
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rallybio Corp (RLYB.O) is -1.05, compared to its 5-year average forward P/E of -2.37. For a more detailed relative valuation and DCF analysis to assess Rallybio Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.37
Current PE
-1.05
Overvalued PE
-0.63
Undervalued PE
-4.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.72
Undervalued EV/EBITDA
-1.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
70.04
Current PS
0.00
Overvalued PS
223.07
Undervalued PS
-82.99
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RLYB News & Events

Events Timeline

(ET)
2025-09-25
08:02:28
Rallybio finishes administering doses to initial group in RLYB116 trial
select
2025-09-03 (ET)
2025-09-03
08:11:30
Rallybio Secures $12.5M Equity Milestone Payment from Recursion Pharmaceuticals
select
2025-07-08 (ET)
2025-07-08
08:13:26
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-10NASDAQ.COM
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours

  • InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.

  • Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.

  • FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.

  • Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.

[object Object]
Preview
9.5
11-06Newsfilter
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments

  • RLYB116 Study Progress: Rallybio has completed dosing for Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD study, with data expected in Q4 2025, targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.

  • Financial Highlights: The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027, and reported a net income of $16 million for Q3 2025, a significant improvement from a net loss in the same period last year.

[object Object]
Preview
2.0
10-03NASDAQ.COM
Post-Market Activity: Biotech and Medtech Stocks Surge on Increased Volume and Announcements

  • Biotech Stock Movements: Several biotech and medical device stocks experienced significant after-hours gains, with Reviva Pharmaceuticals (RVPH) leading the surge with an 18.27% increase, driven by high trading volume and recent catalysts related to its lead candidate brilaroxazine.

  • Company Updates and Guidance: Penumbra Inc. (PEN) and Palisade Bio Inc. (PALI) also saw notable increases, with PEN benefiting from executive changes and positive revenue guidance, while PALI's rise was linked to a successful public offering and clinical updates.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rallybio Corp (RLYB) stock price today?

The current price of RLYB is 0.6666 USD — it has increased 1.06 % in the last trading day.

arrow icon

What is Rallybio Corp (RLYB)'s business?

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

arrow icon

What is the price predicton of RLYB Stock?

Wall Street analysts forecast RLYB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLYB is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rallybio Corp (RLYB)'s revenue for the last quarter?

Rallybio Corp revenue for the last quarter amounts to 212.00K USD, decreased -29.10 % YoY.

arrow icon

What is Rallybio Corp (RLYB)'s earnings per share (EPS) for the last quarter?

Rallybio Corp. EPS for the last quarter amounts to 0.36 USD, decreased -238.46 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rallybio Corp (RLYB)'s fundamentals?

The market is revising Upward the revenue expectations for Rallybio Corporation (RLYB) for FY2025, with the revenue forecasts being adjusted by 39.75% over the past three months. During the same period, the stock price has changed by 9.53%.
arrow icon

How many employees does Rallybio Corp (RLYB). have?

Rallybio Corp (RLYB) has 25 emplpoyees as of December 05 2025.

arrow icon

What is Rallybio Corp (RLYB) market cap?

Today RLYB has the market capitalization of 28.16M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free